Empery Asset Management’s BriaCell Therapeutics Corp Warrant BCTXZ Stock Holding History

Empery Asset Management’s Portfolio BCTXZ Stock Details BCTXZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-666,600	Closed	-$93.3K	–	42
2026 Q1	$93.3K	Hold	666,600	–	–	0.11%	22
2025 Q4	$193K	Buy	+666,600	New	+$248K	0.17%	18

Other funds holding BCTXZ

HCM

Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Empery Asset Management's BCTXZ Position: Q2 2026 in Review

Empery Asset Management sold out of BriaCell Therapeutics Corp Warrant (BCTXZ) in Q2 2026, closing a stake of 666,600 shares — an estimated $93.3K sold.

Empery Asset Management first reported a position in BCTXZ in Q4 2025 and held it in 2 quarters. The position peaked at $193K in Q4 2025. 5 funds tracked by Wall St. Rank hold BCTXZ as of Q2 2026.

Empery Asset Management reported no remaining BriaCell Therapeutics Corp Warrant position as of Q2 2026 after selling out during the quarter.
Empery Asset Management sold 666,600 BriaCell Therapeutics Corp Warrant shares in Q2 2026, an estimated $93.3K.
Empery Asset Management first reported a position in BriaCell Therapeutics Corp Warrant in Q4 2025 and held it in 2 quarters.
Empery Asset Management's BriaCell Therapeutics Corp Warrant position peaked at $193K in Q4 2025.
5 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q2 2026.

Based on Empery Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.